Rigorously researched, market-focused
forecast models

Evidence‑driven epidemiology forecast models for modern drug development

Epivantage specializes in building rigorously researched, high‑resolution epidemiological forecast models designed for the era of genetic medicine, targeted therapies, and increasingly niche drug labels. Our models are available as fully customized solutions or as ready‑to‑download files from our Model Library, giving biopharma teams fast access to defensible, launch‑ready epidemiology.

Built by physician‑epidemiologists using best‑in‑class evidence

Our physician‑epidemiologists conduct systematic reviews of the published literature and perform deep‑dive analyses across both proprietary and publicly available datasets. This evidence base forms the backbone of every model we produce, ensuring scientific credibility and real‑world relevance.

Forecasting eligible patient populations across 26 high‑income markets

Each model is engineered to quantify the eligible patient population for upcoming drug approvals and existing therapies. Forecasts extend over a 20‑year horizon and cover 26 high‑income countries, including China, providing a global view of future treatment opportunity.

A multi‑parameter, evidence‑based forecasting approach

Our forecasting methodology incorporates multiple epidemiological parameters—always grounded in published studies and real‑world datasets. This ensures that every assumption is defensible, transparent, and aligned with the most current understanding of disease epidemiology.

Interactive, updateable, and scenario‑ready

All Epivantage models are interactive and updateable. Every cited estimate can be refreshed as new evidence emerges, and parameters can be adjusted to explore alternative scenarios, evolving medical practice, or shifts in diagnostic pathways. This flexibility empowers teams to plan confidently in dynamic therapeutic landscapes.